Ann: MedAdvisor & Arrow to launch strategic partnership, page-7

MDR progressing very well and believe they are in now real growth phase after completing implementation phase.

Once supply over through to 4c. This will quickly climb and set to 6c.

MC is very low and it has first mover advantage in AUS & NZ when comes to GP-Pharma apps. Even they can't earn big money from subscription but would be able to earn good revenue from advertising.

Once RAP re-listed, it was held back with some good supply between 2-2.5c. However, since market realized the potential, it just kept climbing.

Not saying MDR will fly like RAP but it has potential to sit around 6-8c until some great financial (Revenue/profit) figures is out.

cheers
J